ARTICLE | Financial News

Heron raises $150M in follow-on

December 5, 2017 10:22 PM UTC

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $150 million in a follow-on underwritten by Cantor Fitzgerald.

The company markets Sustol granisetron extended release (APF530) to prevent chemotherapy-induced nausea and vomiting (CINV). The product is a long-acting formulation of a serotonin (5-HT3) receptor antagonist formulated using Heron's Biochronomer polymer-based drug delivery technology...